Replies to post #9607 on Aurinia Pharmaceuticals Inc (AUPH)

[Awlau]

Thanks cool! I think aurora2 enrollment would be a good way to get a sense about the p3. I don’t see many people rolling over to a 24 month trial if VOC wasn’t working for them and put them into remission

[CoolG73]

from 9 August 2018 NR : " We are excited to announce that the AURORA Phase III trial in lupus nephritis is running ahead of schedule and we now anticipate completing enrollment in early Q4 2018. We are extremely pleased with the trial’s progress thus far and having patients roll over into the AURORA 2 extension study reinforces our confidence in the program"

from 8 Nov 2018 NR : "A significant percentage of patients who have completed the AURORA trial are rolling over into the AURORA 2 blinded extension study (“AURORA 2”) from the AURORA Phase III clinical trial. The purpose of AURORA 2 is to assess the long-term benefit/risk of voclosporin in patients with LN; however, this study is not a requirement for potential regulatory approval for voclosporin"